TransEnterix, Inc. (TRXC): Price and Financial Metrics
TRXC Stock Summary
- TRXC's price/sales ratio is 147.91; that's higher than the P/S ratio of 97.28% of US stocks.
- Revenue growth over the past 12 months for Transenterix Inc comes in at -82.07%, a number that bests merely 1.67% of the US stocks we're tracking.
- In terms of volatility of its share price, TRXC is more volatile than 99.43% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to Transenterix Inc, a group of peers worth examining would be GNMK, DMRC, PSTG, RDFN, and GKOS.
- TRXC's SEC filings can be seen here. And to visit Transenterix Inc's official web site, go to www.transenterix.com.
TRXC Stock Price Chart Interactive Chart >
TRXC Price/Volume Stats
|Current price||$4.08||52-week high||$6.95|
|Prev. close||$4.54||52-week low||$0.28|
|Day high||$4.77||Avg. volume||44,558,918|
|50-day MA||$3.04||Dividend yield||N/A|
|200-day MA||$1.09||Market Cap||582.53M|
TransEnterix, Inc. (TRXC) Company Bio
TransEnterix, Inc. focuses on the development and commercialization of a robotic assisted surgical system in the United States and internationally. The company is based in Morrisville, North Carolina.
TRXC Latest News Stream
|Loading, please wait...|
TRXC Latest Social Stream
View Full TRXC Social Stream
Latest TRXC News From Around the Web
Below are the latest news stories about Transenterix Inc that investors may wish to consider to help them evaluate TRXC as an investment opportunity.
Asensus Surgical, Inc. Schedules Fourth Quarter and Fiscal Year 2020 Financial and Operating Results Conference Call for March 11, 2021
Asensus Surgical, Inc. (NYSE American: TRXC) (formerly TransEnterix, Inc.), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, announced today that it plans to release fourth quarter and fiscal year 2020 financial and operating results after the market closes on Thursday, March 11, 2021. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast.
Asensus Surgical, Inc. (formerly TransEnterix, Inc.) (NYSE American: TRXC) , a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, today announced the Company has received an additional FDA clearance for the Senhance Surgical System which allows for indication expansion in general surgery in the United States.
TransEnterix (TRXC) closed at $3.72 in the latest trading session, marking no change from the prior day.
Asensus Surgical, Inc. (NYSE American: TRXC) (formerly TransEnterix, Inc.), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery, announced today that Anthony Fernando, President and Chief Executive Officer, and Shameze Rampertab, Executive Vice President and Chief Financial Officer, will participate in the H.C. Wainwright Virtual Global Life Sciences Conference taking place March 9 and March 10, 2021.
Shares of the robotic surgical-system manufacturer are soaring, but can this company become the next Intuitive Surgical?
TRXC Price Returns
Continue Researching TRXCWant to do more research on Transenterix Inc's stock and its price? Try the links below:
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!